Top Price Market
  • Business
  • Politics
  • Investing
  • World
  • Business
  • Politics
  • Investing
  • World

Top Price Market

Investing

FDA Fast Track Designation for Narmafotinib in Advanced Pancreatic Cancer

by September 20, 2024
September 20, 2024
FDA Fast Track Designation for Narmafotinib in Advanced Pancreatic Cancer

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to Amplia’s Focal Adhesion Kinase inhibitor, narmafotinib, for the treatment of advanced pancreatic cancer.

HIGHLIGHTS

The US FDA has granted Fast Track Designation to Amplia’s lead drug narmafotinib in advanced pancreatic cancerFast Track Designation facilitates the development of investigational drugs and allows for expedited review

Fast Track Designation is available to drugs that may provide an advantage over current therapies in the treatment of serious conditions. It is designed to speed the development of these drugs to enable patients to receive them sooner. This Designation will grant the Company access to more frequent meetings, and written communication, with the FDA. In future, narmafotinib may be eligible for Accelerated Approval and Priority Review. The Company has previously received Orphan Drug Designation from the FDA for narmafotinib in pancreatic cancer.

The Company’s CEO and Managing Director, Dr Chris Burns, commented, “Fast Track Designation for narmafotinib is a significant milestone for the Company. With this designation, we can work more closely with the FDA to accelerate our clinical program and gather the most compelling evidence for regulatory approval in this devastating disease.”

Amplia’s clinical trial in advanced pancreatic cancer, the ACCENT trial, is ongoing in Australia and South Korea. Earlier this year, the Company announced that the US FDA had cleared its IND1 application for a trial of narmafotinib in pancreatic cancer in the US. This trial is in advanced planning stages.

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

Click here for the full ASX Release

This post appeared first on investingnews.com
0
FacebookTwitterGoogle +Pinterest
previous post
Saskatchewan Research Council Achieves Commercial Production at Rare Earths Facility
next post
Newsom’s deepfake election laws are already being challenged in federal court

You may also like

Fortune Minerals Announces Second Draw From Convertible Securities...

Appia Announces Outstanding Re-Assayed Diamond Drill Results Including...

Heritage Mining Further Expands Land Position and Provides...

Cizzle Brands Strengthens U.S. Footprint of CWENCH Hydration...

First Diamond Drilling Results at Ricciardo Deliver High-Grade...

Osisko Metals to Participate in THE Mining Investment...

Persistent Systems Selects Zscaler to Launch Technology Modernization...

Charbone Hydrogen Announces Q2 2024 Financial Results

Orla to Buy Musselwhite Gold Mine from Newmont...

Altech Batteries LtdBreakthrough 55% Higher Energy Density Anodes

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • Israel’s plan to ‘conquer’ Gaza is leaving Palestinians with little place to...

    • US calls for Asia allies to boost defenses in face of China’s ‘imminent’ threat, Hegseth tells top defense forum

    • Top 5 Canadian Mining Stocks This Week: Adyton Sparkles with 97 Percent Gain

    • Hunter Biden seen driving Toyota rental in South Africa after his Secret Service detail was terminated

    • These toys are so hot that Chinese customs agents have seized hundreds of them in recent weeks

    Categories

    • Business (1,672)
    • Investing (4,988)
    • Politics (7,848)
    • Uncategorized (2)
    • World (6,353)
    • About us
    • Contacts
    • Privacy Policy
    • Terms & Conditions
    • Email Whitelisting

    Disclaimer: toppricemarket.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 toppricemarket.com | All Rights Reserved


    Back To Top